Niacinamide

Niacinamide

SCHEMBL460466

NC(=O)c1cccnc1.NC(=O)c1cccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 1.00
F3 P13726 1/20 1.00
SARM1 Q6SZW1 1/20 1.00
SIRT2 Q8IXJ6 1/20 1.00
SIRT6 Q8N6T7 1/20 1.00
SIRT1 Q96EB6 1/20 1.00
SIRT3 Q9NTG7 1/20 1.00
SIRT5 Q9NXA8 1/20 1.00
SIRT4 Q9Y6E7 1/20 1.00
ALDH1A1 P00352 2/20 0.65
APP P05067 1/20 0.65
GAA P10253 1/20 0.65
HCAR3 P49019 1/20 0.65
HCAR2 Q8TDS4 1/20 0.65
MKNK1 Q9BUB5 3/20 0.63
MKNK2 Q9HBH9 3/20 0.63
HDAC1 Q13547 2/20 0.59
HDAC6 Q9UBN7 1/20 0.59
POLB P06746 2/20 0.55
PLOD2 O00469 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niacinamide SCHEMBL29624874 1.00
Niacinamide SCHEMBL2926 1.00
Niacinamide SCHEMBL19978192 1.00
Niacinamide SCHEMBL6702885 0.98 F7 (0.96) F7F3SARM1SIRT2SIRT6
Niacinamide SCHEMBL9373225 0.98 F7 (0.96) F7F3SARM1SIRT2SIRT6
Niacinamide SCHEMBL25366418 0.98
Niacinamide SCHEMBL11870926 0.98 F7 (0.96) F7F3SARM1SIRT2SIRT6
Niacinamide SCHEMBL1220080 0.98 F7 (0.96) F7F3SARM1SIRT2SIRT6
Niacinamide SCHEMBL9949818 0.98 F7 (0.96) F7F3SARM1SIRT2SIRT6
Niacinamide SCHEMBL23576525 0.98 F7 (0.96) F7F3SARM1SIRT2SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113430170-A Primary human intestinal cancer cell and culture method and application thereof 北京和合医学诊断技术股份有限公司 2021-09-24 CN claimed
CN-113278589-A Primary human intestinal cancer cell and culture method and application thereof 北京和合医学诊断技术股份有限公司 2021-08-20 CN claimed
US-20090151598-A1 combination of passivating agents which evaporate or sublimate to temporarily prevent metal corrosion in packaging; a C6-10 aliphatic monocarboxylic acid;a C6-10 aliphatic dicarboxylic acid; a primary aromatic amide; an aliphatic ester of hydroxybenzoic acid; a benzimidazole EXCOR KORROSIONSFORSCHUNG GMBH (DE) 2009-06-18 US claimed
WO-2024126604-A1 PROCESS FOR PREPARING A COSMETIC ARTICLE AND COSMETIC ARTICLE THAT IS ADAPTABLE TO THE SHAPE OF THE FACE, NECK AND/OR NECKLINE AND CHARGED WITH HYDROPHILIC ACTIVE AGENT L'OREAL (FR) 2024-06-20 WO disclosed
CN-112569162-B Synergistic effect of radix Ophiopogonis extract, amino acid derivative and calcium lactate hydrate 默克专利股份有限公司 2024-04-12 CN disclosed
WO-2024058984-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2024-03-21 WO disclosed
CN-116836933-B Liver and gall cancer organoid culture solution, culture reagent combination and culture method 北京大橡科技有限公司 2024-01-02 CN disclosed
CN-116814551-B Pancreatic cancer organoid culture solution, culture reagent combination and culture method 北京大橡科技有限公司 2023-11-24 CN disclosed
CN-116836933-A Liver and gall cancer organoid culture solution, culture reagent combination and culture method 北京大橡科技有限公司 2023-10-03 CN disclosed
CN-116814551-A Pancreatic cancer organoid culture solution, culture reagent combination and culture method 北京大橡科技有限公司 2023-09-29 CN disclosed
WO-2023126397-A1 KIT FOR CUSTOMIZING A COSMETIC COMPOSITION L'OREAL (FR) 2023-07-06 WO disclosed
WO-2005060711-A2 METHODS OF TREATING A DISORDER ELIXIR PHARMACEUTICALS, INC. (US) 2005-07-07 WO disclosed
CN-1198580-C Skin care compositions containing polysilicone elastomers PROCTER & GAMBLE (US) 2005-04-27 CN disclosed
WO-2005026112-A2 METHODS OF TREATING A DISORDER ELIXIR PHARMACEUTICALS, INC. (US) 2005-03-24 WO disclosed
CN-1441665-A Skin care compositions containing polysilicone elastomers PROCTER & GAMBLE (US) 2003-09-10 CN disclosed
EP-1207840-A4 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR REDUCING THE APPEARANCE OF CELLULITE MURAD HOWARD (US) 2002-10-30 EP disclosed
EP-1207840-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR REDUCING THE APPEARANCE OF CELLULITE Murad, Howard (US) 2002-05-29 EP disclosed
US-6207190-B1 SYNERGISTIC MIXTURE TO REDUCE OCULAR PRESSURE AND IMPROVE VASCULAR HEALTH COMPRISING FOLIC ACID, A MAGNESIUM SALT, ALPHA-TOCOPHEROL, ASCORBATE AND ALPHA-LIPOIC ACID CHRONORX, LLC 2001-03-27 US disclosed
WO-2001013865-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR REDUCING THE APPEARANCE OF CELLULITE MURAD HOWARD (US) 2001-03-01 WO disclosed
US-5756650-A COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS KABUSHIKI KAISHA TOSHIBA (JP) 1998-05-26 US disclosed